Pharmasset News

Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.

The biotech sector has always been risky due to the fact that its product pipeline is affected by FDA approval and risks in the development of products.

Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained in extended trading after saying one of the therapies produced positive clinical trial results.

The line between big pharma and big biotech has become increasingly blurry as the four big biotechs have grown up.

So what: Stifel Nicolaus slapped the dreaded sell rating on Idenix this morning, downgrading it from neutral.

You don't find too many wealthy do it yourselfers. While some people of means still enjoy putting in the hard work, knowing that a project was done correctly, most prefer to supervise, letting someone else to the heavy lifting.

Finding cures for diseases is always a tall order to take up on, but to have a drug that can cure a disease without fail is almost too good to be true.

The past 6 months have proven that biotech mergers & acquisitions are soaring. Gilead gobbled up Pharmasset , and Bristol-Myers bought Inhibitex , and dozens of companies are rumored to be next.

NEW YORK -- Wall Street investors remain bullish on hepatitis C drug stocks and by a wide margin believe Idenix Pharmaceuticals ISI Group biotech analyst Mark Schoenebaum held a lunch meeting Friday for 120 investors to discuss the current state of hepatitis C drug development.

Hepatitus C drug developers have been drinking champagne and eating caviar lately.

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Royal Merger Sub II Inc., a wholly-owned subsidiary of Gilead , to acquire Pharmasset, Inc.

The atmosphere at the 30th annual J. P. Morgan Healthcare Conference in San Francisco last week was charged with enthusiasm in the wake of deals indicating that drug companies are prepared to invest in innovative science.